Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferoxamine plus chemotherapy in metastatic TNBC
NCT05300958Phase 2Terminated
- Sponsor
- Sun Yat-sen University
- Start
- Mar 2022
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of deferoxamine in triple-negative breast cancer (TNBC), sponsored by Sun Yat-sen University. Primary endpoint: Objective Response Rate at 6 months. Started Mar 2022; status: terminated.
02
Drugs
deferoxamine
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05300958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05300958.